Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADINASDAQ:ETONNASDAQ:GLSINASDAQ:IMNM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$2.05+2.0%$1.72$1.21▼$3.81$50.63M0.68265,147 shs110,365 shsETONEton Pharmaceuticals$13.70+0.7%$16.66$3.18▼$21.48$367.40M1.28227,647 shs341,413 shsGLSIGreenwich LifeSciences$8.92-1.2%$9.61$8.06▼$18.15$119.25M1.6946,222 shs34,228 shsIMNMImmunome$8.83-1.3%$8.45$5.15▼$16.81$768.32M1.94917,910 shs740,253 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience+1.99%+2.50%+16.48%+4.59%+27.33%ETONEton Pharmaceuticals0.00%-5.58%-30.10%-3.66%+320.25%GLSIGreenwich LifeSciences0.00%-5.81%-13.40%-19.71%-44.15%IMNMImmunome0.00%-9.81%+3.15%+7.95%-33.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAADIAadi Bioscience0.602 of 5 stars1.00.00.00.01.12.51.3ETONEton Pharmaceuticals2.5317 of 5 stars3.53.00.00.01.91.70.6GLSIGreenwich LifeSciences1.9724 of 5 stars3.51.00.00.00.03.30.0IMNMImmunome1.6048 of 5 stars3.50.00.00.02.22.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 2.00Hold$1.67-18.70% DownsideETONEton Pharmaceuticals 3.00Buy$29.67116.55% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00337.22% UpsideIMNMImmunome 3.00Buy$23.33164.25% UpsideCurrent Analyst Ratings BreakdownLatest AADI, GLSI, IMNM, and ETON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025ETONEton PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $35.005/16/2025ETONEton PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $26.005/14/2025ETONEton PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$26.00 ➝ $28.005/13/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $21.004/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.004/2/2025IMNMImmunomeLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.003/20/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.00 ➝ $33.003/20/2025IMNMImmunomeStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.003/20/2025IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$35.00 ➝ $25.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M2.02N/AN/A$4.29 per share0.48ETONEton Pharmaceuticals$39.01M9.42N/AN/A$0.94 per share14.57GLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/AIMNMImmunome$9.04M84.99N/AN/A$2.27 per share3.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%8/5/2025 (Estimated)ETONEton Pharmaceuticals-$3.82M-$0.18N/A27.40N/A-9.49%-3.15%-1.08%8/4/2025 (Estimated)GLSIGreenwich LifeSciences-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/12/2025 (Estimated)IMNMImmunome-$292.96M-$3.18N/AN/AN/A-1,875.21%-71.65%-60.36%8/11/2025 (Estimated)Latest AADI, GLSI, IMNM, and ETON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/13/2025Q1 2025ETONEton Pharmaceuticals$0.09$0.07-$0.02-$0.06$14.33 million$17.28 million5/12/2025Q1 2025IMNMImmunome-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54ETONEton Pharmaceuticals1.231.971.43GLSIGreenwich LifeSciencesN/A1.911.91IMNMImmunomeN/A10.4910.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%ETONEton Pharmaceuticals27.86%GLSIGreenwich LifeSciences4.16%IMNMImmunome44.58%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%ETONEton Pharmaceuticals16.03%GLSIGreenwich LifeSciences51.67%IMNMImmunome8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionableETONEton Pharmaceuticals2026.82 million22.52 millionOptionableGLSIGreenwich LifeSciences313.37 million6.46 millionNot OptionableIMNMImmunome4087.01 million79.53 millionOptionableAADI, GLSI, IMNM, and ETON HeadlinesRecent News About These CompaniesImmunome, Inc. (NASDAQ:IMNM) Receives Average Rating of "Buy" from AnalystsJune 19 at 4:26 AM | marketbeat.comImmunome (IMNM) Upgraded to Buy: Here's What You Should KnowJune 16, 2025 | zacks.comImmunome (NASDAQ:IMNM) Trading Down 6.7% - Should You Sell?June 13, 2025 | marketbeat.comWall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?June 12, 2025 | zacks.comBank of America Corp DE Sells 44,020 Shares of Immunome, Inc. (NASDAQ:IMNM)June 12, 2025 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Shares Sold by Jane Street Group LLCJune 7, 2025 | marketbeat.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2025 | businesswire.comLifesci Capital Has Positive Outlook of Immunome Q2 EarningsJune 5, 2025 | marketbeat.comTwo Sigma Advisers LP Makes New $512,000 Investment in Immunome, Inc. (NASDAQ:IMNM)June 5, 2025 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Director Buys $46,900.00 in StockJune 5, 2025 | marketbeat.comInsider Buying: Immunome, Inc. (NASDAQ:IMNM) Director Buys 5,000 Shares of StockJune 4, 2025 | insidertrades.comTwo Sigma Investments LP Purchases Shares of 154,467 Immunome, Inc. (NASDAQ:IMNM)June 3, 2025 | marketbeat.comMillennium Management LLC Buys New Position in Immunome, Inc. (NASDAQ:IMNM)June 3, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Trading Up 4.5% - Here's WhyMay 30, 2025 | marketbeat.comWall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a BetMay 26, 2025 | zacks.comImmunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of "Buy" by BrokeragesMay 26, 2025 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Shares Bought by Woodline Partners LPMay 25, 2025 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Shares Acquired by Northern Trust CorpMay 23, 2025 | marketbeat.comPoint72 Asset Management L.P. Raises Stock Holdings in Immunome, Inc. (NASDAQ:IMNM)May 22, 2025 | marketbeat.comImmunome, Inc. Reports Q1 2025 Financial ResultsMay 21, 2025 | tipranks.comAll You Need to Know About Immunome (IMNM) Rating Upgrade to BuyMay 13, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAADI, GLSI, IMNM, and ETON Company DescriptionsAadi Bioscience NASDAQ:AADI$2.05 +0.04 (+1.99%) As of 06/18/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Eton Pharmaceuticals NASDAQ:ETON$13.70 +0.09 (+0.66%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$14.25 +0.55 (+4.01%) As of 06/18/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Greenwich LifeSciences NASDAQ:GLSI$8.92 -0.11 (-1.22%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$9.27 +0.35 (+3.97%) As of 06/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Immunome NASDAQ:IMNM$8.83 -0.12 (-1.34%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$9.11 +0.28 (+3.17%) As of 06/18/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
